Loading
The confirmatory trial for the first c-MET ADC, which was approved early on response rate alone.
TeliMET NSCLC-01, trial NCT04928846 sponsored by AbbVie, is the randomised phase 3 confirmatory trial for telisotuzumab vedotin, the first c-MET antibody-drug conjugate, which received accelerated approval in May 2025 on response rate alone. It compares telisotuzumab vedotin with docetaxel in previously treated c-Met-overexpressing, EGFR-wild-type non-squamous non-small-cell lung cancer and plans to enrol 768 patients, with enrolment ongoing and no results available. The accelerated approval rested on the single-arm LUMINOSITY study, in which about a third of patients with high c-Met expression responded, and OnCo links the trial to MET as a target. Whether a response-rate approval converts into a survival advantage over chemotherapy is exactly what this trial exists to answer. Telisotuzumab vedotin has its own page.
Shares Telisotuzumab vedotin, MET exon 14 and MET-amplified non-small-cell lung cancer, AbbVie (incl. ImmunoGen, Capstan), Antibody-drug conjugate (ADC).
Shares MET exon 14 and MET-amplified non-small-cell lung cancer, MET, Non-small-cell lung cancer.
Shares Telisotuzumab vedotin, MET exon 14 and MET-amplified non-small-cell lung cancer, MET, AbbVie (incl. ImmunoGen, Capstan).
Shares Telisotuzumab vedotin, MET exon 14 and MET-amplified non-small-cell lung cancer, Antibody-drug conjugate (ADC).
Shares Telisotuzumab vedotin, MET, Non-small-cell lung cancer.
Shares MET exon 14 and MET-amplified non-small-cell lung cancer, Non-small-cell lung cancer.
Shares MET exon 14 and MET-amplified non-small-cell lung cancer, AbbVie (incl. ImmunoGen, Capstan), Antibody-drug conjugate (ADC).
Shares AbbVie (incl. ImmunoGen, Capstan), Antibody-drug conjugate (ADC).